BRPI1014027A2 - suspensão de fármaco de nanopartícula estável. - Google Patents
suspensão de fármaco de nanopartícula estável.Info
- Publication number
- BRPI1014027A2 BRPI1014027A2 BRPI1014027A BRPI1014027A BRPI1014027A2 BR PI1014027 A2 BRPI1014027 A2 BR PI1014027A2 BR PI1014027 A BRPI1014027 A BR PI1014027A BR PI1014027 A BRPI1014027 A BR PI1014027A BR PI1014027 A2 BRPI1014027 A2 BR PI1014027A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug suspension
- nanoparticle drug
- stable nanoparticle
- stable
- suspension
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21828109P | 2009-06-18 | 2009-06-18 | |
| PCT/US2010/038526 WO2010147899A1 (en) | 2009-06-18 | 2010-06-14 | Stable nanoparticulate drug suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014027A2 true BRPI1014027A2 (pt) | 2019-09-24 |
Family
ID=42797219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014027A BRPI1014027A2 (pt) | 2009-06-18 | 2010-06-14 | suspensão de fármaco de nanopartícula estável. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100323020A1 (pt) |
| EP (1) | EP2442789A1 (pt) |
| JP (1) | JP2012530704A (pt) |
| KR (1) | KR20120052937A (pt) |
| CN (1) | CN102802609A (pt) |
| AU (1) | AU2010260226A1 (pt) |
| BR (1) | BRPI1014027A2 (pt) |
| CA (1) | CA2764187A1 (pt) |
| IL (1) | IL216593A0 (pt) |
| MX (1) | MX2011013797A (pt) |
| RU (1) | RU2012101627A (pt) |
| SG (1) | SG176929A1 (pt) |
| TW (1) | TW201103573A (pt) |
| WO (1) | WO2010147899A1 (pt) |
| ZA (1) | ZA201109219B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| WO2011079127A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| US20130089575A1 (en) * | 2011-10-05 | 2013-04-11 | Douglas Pharmaceuticals Ltd. | Pharmaceutical methods and topical compositions containing acitretin |
| AU2014226290B2 (en) * | 2013-03-04 | 2018-11-15 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
| US9598377B2 (en) | 2013-03-12 | 2017-03-21 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| KR20170008252A (ko) * | 2014-05-09 | 2017-01-23 | 아우로메딕스 파마 엘엘씨 | 사이클로포스파미드 액상 농축 제제 |
| EP3236903B1 (en) | 2014-12-23 | 2021-04-21 | Intellectual Property Associates, LLC | Methods and formulations for transdermal administration |
| JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク． | フルベストラント配合物およびその使用方法 |
| US11207307B2 (en) | 2016-06-16 | 2021-12-28 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
| US20200031920A1 (en) * | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| EP3681479B1 (en) * | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| JP7355741B2 (ja) | 2018-01-10 | 2023-10-03 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | ベンズアミド化合物 |
| JP2021530542A (ja) * | 2018-07-24 | 2021-11-11 | ジャニュアリー セラピューティクス，インク． | ナノ粒子組成物 |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| EP4054585A1 (en) | 2019-11-05 | 2022-09-14 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| US20210169903A1 (en) * | 2019-12-09 | 2021-06-10 | Tyme, Inc. | Pharmaceutical compositions and methods |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1471887T3 (da) | 2002-02-04 | 2010-06-07 | Elan Pharma Int Ltd | Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
| CN101534904B (zh) * | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
| WO2009073835A1 (en) * | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
-
2010
- 2010-06-14 RU RU2012101627/15A patent/RU2012101627A/ru unknown
- 2010-06-14 JP JP2012516170A patent/JP2012530704A/ja not_active Withdrawn
- 2010-06-14 EP EP10724981A patent/EP2442789A1/en not_active Withdrawn
- 2010-06-14 AU AU2010260226A patent/AU2010260226A1/en not_active Abandoned
- 2010-06-14 CN CN2010800368047A patent/CN102802609A/zh active Pending
- 2010-06-14 MX MX2011013797A patent/MX2011013797A/es not_active Application Discontinuation
- 2010-06-14 WO PCT/US2010/038526 patent/WO2010147899A1/en active Application Filing
- 2010-06-14 SG SG2011094406A patent/SG176929A1/en unknown
- 2010-06-14 CA CA2764187A patent/CA2764187A1/en not_active Abandoned
- 2010-06-14 BR BRPI1014027A patent/BRPI1014027A2/pt not_active IP Right Cessation
- 2010-06-14 KR KR1020127001358A patent/KR20120052937A/ko not_active Application Discontinuation
- 2010-06-17 US US12/817,640 patent/US20100323020A1/en not_active Abandoned
- 2010-06-18 TW TW099119972A patent/TW201103573A/zh unknown
-
2011
- 2011-11-24 IL IL216593A patent/IL216593A0/en unknown
- 2011-12-14 ZA ZA2011/09219A patent/ZA201109219B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120052937A (ko) | 2012-05-24 |
| MX2011013797A (es) | 2012-01-30 |
| AU2010260226A1 (en) | 2012-02-02 |
| EP2442789A1 (en) | 2012-04-25 |
| RU2012101627A (ru) | 2013-07-27 |
| JP2012530704A (ja) | 2012-12-06 |
| ZA201109219B (en) | 2013-05-29 |
| CA2764187A1 (en) | 2010-12-23 |
| WO2010147899A1 (en) | 2010-12-23 |
| IL216593A0 (en) | 2012-02-29 |
| US20100323020A1 (en) | 2010-12-23 |
| CN102802609A (zh) | 2012-11-28 |
| TW201103573A (en) | 2011-02-01 |
| SG176929A1 (en) | 2012-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014027A2 (pt) | suspensão de fármaco de nanopartícula estável. | |
| BRPI0906611A2 (pt) | Produtos implantáveis compreendendo nanopartículas. | |
| HRP20170959T1 (hr) | Farmaceutska suspenzija | |
| BRPI0920514A2 (pt) | infusão de fármacos | |
| BR112012011902A2 (pt) | cápsula farmacêutica | |
| BR112012008156A2 (pt) | conjunto de cateter com abertura reselável | |
| BRPI1014982A2 (pt) | dispositivo de suspensão | |
| BRPI1016117A8 (pt) | derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| BRPI1008899A2 (pt) | derivados 3,3´-espiroindolinona como agentes anticâncer | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| BRPI1016190A2 (pt) | compostos farmacêuticos. | |
| BRPI1013235A2 (pt) | suspensão de veículo | |
| BRPI1014388A2 (pt) | preparação de sólido. | |
| BRPI1016192A2 (pt) | derivados de soxazol. | |
| DK2442870T3 (da) | Pyrazinooxazepin-derivater. | |
| DK2506831T3 (da) | Carboxyvinylpolymerholdige nanopartikelsuspensioner | |
| BRPI1014897A8 (pt) | dispositivo de suspensão. | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer | |
| BR112012000654A2 (pt) | estruturas de suspensao | |
| BRPI1016203A2 (pt) | diferencial | |
| BR112012001680A2 (pt) | Derivados de tazaroteno | |
| BRPI1010981A2 (pt) | "derivados de fármaco redox" | |
| BRPI1010060A2 (pt) | diferencial | |
| IT1401713B1 (it) | Supporto intervertebrale. | |
| BRPI0822924A2 (pt) | Veículo de fármaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |